Notice of Allowability	Application No.	Applicant(s)
	09/436,892	MEDFORD ET AL.
	Examiner	Art Unit
	Gailene R. Gabel	1641
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGOR (The Office or upon petition by the applicant. See 37 CFR 1.313 1. This communication is responsive to Applicant's amendment 2. The allowed claim(s) is/are 9, 15, 29, 31, 32, 35, 36, 40, and	OR REMAINS) CLOSED in this apport of the appropriate communication GHTS. This application is subject that MPEP 1308.  Internal of the application is subject that the application is subject that and MPEP 1308.	oplication. If not included n will be mailed in due course. <b>THIS</b> to withdrawal from issue at the initiative
3. The drawings filed on <u>07 May 2001</u> are accepted by the Examiner.		
4. ☐ Acknowledgment is made of a claim for foreign priority under a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority docimentational Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONME THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted in INFORMAL PATENT APPLICATION (PTO-152) which gives are considered by the Notice of Draftsperso and including changes required by the Notice of Draftsperso and including changes required by the attached Examiner's and Paper No./Mail Date  [b) ☐ including changes required by the attached Examiner's and Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1.8 each sheet. Replacement sheet(s) should be labeled as such in the paper No./Mail Date	been received. been received in Application No uments have been received in this  If this communication to file a reply ENT of this application.  Ited. Note the attached EXAMINER Is reason(s) why the oath or declarate be submitted. In's Patent Drawing Review (PTO-I Amendment / Comment or in the O  If (c)) should be written on the drawing header according to 37 CFR 1.121(c)  It of BIOLOGICAL MATERIAL meaning the service of the service	national stage application from the complying with the requirements  'S AMENDMENT or NOTICE OF tion is deficient.  948) attached  Office action of the back) of ti).
Attachment(s)  I. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/08)     Paper No./Mail Date 3/2/00 and 5/8/00  4. ☐ Examiner's Comment Regarding Requirement for Deposit     of Biological Material	6. ⊠ Interview Summary ( Paper No./Mail Date 7. ⊠ Examiner's Amendm	e <u>12/7/04</u> .

Application/Control Number: 09/436,892

Art Unit: 1641

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sherry Knowles on 12/7/04.

2. The application has been amended as follows:

In claim 9, step iii) "using" has been deleted and --adding-- has been inserted therefor.

In claim 9, step iii) after "which binds to", --apoB-100 in-- has been inserted.

In claim 9, step iv) after "a third antibody", --that binds the second antibody and-has been inserted. Further after "to which is attached a label", "and binds the second antibody" has been deleted.

In claim 9, step vi), third line after "low density lipoprotein captured indicates", "an" has been deleted and --a change in the structure of apoB-100 in the cholesterol-containing low density lipoprotein, thus-- has been inserted. Thereafter, "increased" has been deleted and --increasing-- has been inserted therefor.

In claim 40, step iii) after "a second antibody", --which binds the apoB-100 in the combination and-- has been inserted. Further after "to which is attached a label", "and binds the combination" has been deleted.

In claim 40, step v), third line after "low density lipoprotein captured indicates", "an" has been deleted and --a change in the structure of apoB-100 in the cholesterol-containing low density lipoprotein, thus-- has been inserted. Thereafter, "increased" has been deleted and --increasing-- has been inserted therefor.

- 3. Claims 7, 8, 11-14, 16-20, and 37-39 have been cancelled.
- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R. Gabel whose telephone number is (571) 272-0820. The examiner can normally be reached on Monday, Tuesday, and Thursday, 7:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gailene R. Gabel Patent Examiner Art Unit 1641 December 7, 2004 Christyl L. Christopher L. Christopher L. Chin PRIMARY EXAMINER GROUP 1800/64/

nloloy